<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04895462</url>
  </required_header>
  <id_info>
    <org_study_id>CHUV - Stroke&amp;COVID</org_study_id>
    <nct_id>NCT04895462</nct_id>
  </id_info>
  <brief_title>Acute Revascularization Treatment in Ischemic Stroke Patients With COVID-19</brief_title>
  <official_title>Safety and Outcomes of Acute Revascularization Treatment in COVID Patients: an International Comparative Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Vaudois</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Larissa University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Society of Vascular and Interventional Neurology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital de Egas Moniz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire Vaudois</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Case-series and cohort studies have shown the feasibility of reperfusion therapies in&#xD;
      patients with ischemic stroke and COVID-19, but due to the absence of a contemporary control&#xD;
      group of non-COVID-19 patients, small sample size or lack of long-term outcome assessment,&#xD;
      concerns regarding safety and efficacy of these treatments remain to be clarified. Taking&#xD;
      into account its limitations, some studies documented higher rates of endovascular treatment&#xD;
      complications such as clot fragmentation with distal embolization and vessel re-oclusion, to&#xD;
      be more difficult to achieve recanalization after endovascular treatment, and higher rates of&#xD;
      any intracerebral hemmorhage.&#xD;
&#xD;
      The investigators aim is to assess in a large, multicenter and international cohort, the&#xD;
      safety and outcomes of acute reperfusion therapies in patients with ischemic stroke and&#xD;
      COVID-19, by comparison with a contemporary control group of patients with ischemic stroke&#xD;
      and without COVID-19 from the same centers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 30, 2021</start_date>
  <completion_date type="Anticipated">October 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of symptomatic intracranial hemorrhage</measure>
    <time_frame>36 hours</time_frame>
    <description>Symptomatic parenchymal hemorrhagic transformation according to the ECASS-2 (European-Australasian Acute Stroke Study - II) definition, and/or subarachnoid hemorrhage with ≥4-point worsening in NIHSS (National Institute of Health Stroke Scale)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of any hemorrhagic transformation</measure>
    <time_frame>36 hours</time_frame>
    <description>According to the ECASS-2 (European-Australasian Acute Stroke Study - II) definition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of recanalization after endovascular treatment measured by mTICI (modified treatment in cerebral infarction)</measure>
    <time_frame>End of procedure</time_frame>
    <description>Only in EVT patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of successful recanalization after endovascular treatment (defined as final mTICI [modified treatment in cerebral infarction] ≥2b)</measure>
    <time_frame>End of procedure</time_frame>
    <description>Only in EVT patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of passes during endovascular treatment</measure>
    <time_frame>End of procedure</time_frame>
    <description>Only in EVT patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of first pass effect during endovascular treatment</measure>
    <time_frame>End of procedure</time_frame>
    <description>Only in EVT patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of procedural complication (Arterial perforation, embolization into a previously non-ischemic territory, and re-occlusion)</measure>
    <time_frame>End of procedure</time_frame>
    <description>Only in EVT patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delta NIHSS (National Institute of Health Stroke Scale) at 24 hours</measure>
    <time_frame>24 hours</time_frame>
    <description>Difference between admission NIHSS and NIHSS at 24 hours. NIHSS is a scale used to quantify the severity of neurological deficits after stroke: 0 (no signs) to 42 (very severe stroke)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-month modified Rankin Scale (mRS)</measure>
    <time_frame>3 months</time_frame>
    <description>Functional outcome assessed with mRS at 3-month follow-up. The mRS is an ordinal scale that assigns patients among 7 levels of disability: 0 (no symptom) to 5 (severe disability) and 6 (death)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-month favorable outcome</measure>
    <time_frame>3 months</time_frame>
    <description>Favorable outcome defined as modified Rankin Scale (mRS) ≤2 or equal to pre-stroke mRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-month mortality</measure>
    <time_frame>3 months</time_frame>
    <description>Mortality assessed at 3-month follow-up</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Ischemic Stroke</condition>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Ischemic Stroke and COVID-19</arm_group_label>
    <description>Ischemic stroke patients with COVID-19 receiving acute recanalization treatment (intravenous thrombolysis and/or endovascular treatment)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group: Ischemic Stroke without COVID-19</arm_group_label>
    <description>Ischemic stroke patients without COVID-19 receiving acute recanalization treatment (intravenous thrombolysis and/or endovascular treatment)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        1. Exposed group - Patients with COVID-19&#xD;
&#xD;
               -  Community-acquired confirmed case of SARS-CoV-2 infection either by a positive&#xD;
                  PCR- or antigen test, and independently of the presence of identifiable COVID-19&#xD;
                  compatible symptoms&#xD;
&#xD;
               -  Patient hospitalized due to COVID-19 and with in-hospital stroke&#xD;
&#xD;
               -  Patients with COVID-19 compatible symptoms before reperfusion treatment and with&#xD;
                  PCR- or antigen test becoming positive within the first 7 days after treatment&#xD;
&#xD;
          2. Non-exposed group - Patients without COVID-19 (&quot;controls&quot;)&#xD;
&#xD;
               -  Patients without COVID-19 compatible symptoms and with negative PCR- or antigen&#xD;
                  test within the first 7 days after treatment&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        1. Inclusion Criteria:&#xD;
&#xD;
               -  Consecutive ischemic stroke patients receiving acute recanalization treatment&#xD;
                  (intravenous thrombolysis and/or endovascular treatment) up to 24 hours since&#xD;
                  last time since well, and according to local treatment criteria&#xD;
&#xD;
               -  From 1st of March 2020 (for Chinese Centers from 1st January 2020)&#xD;
&#xD;
          2. Exclusion Criteria:&#xD;
&#xD;
               -  Patients without a PCR- or antigen test within the first 7 days after treatment&#xD;
&#xD;
               -  Patients with nosocomial SARS-CoV-2 infection after receiving acute&#xD;
                  recanalization treatment - PCR- or antigen test becoming positive more than 7&#xD;
                  days after treatment&#xD;
&#xD;
               -  Patients with &quot;Suspect/ probable case of SARS-CoV-2 infection&quot; according to the&#xD;
                  World Health Organization definition&#xD;
&#xD;
               -  Symptomatic cases of SARS-CoV-2 infection with symptoms resolution more than 7&#xD;
                  days before treatment&#xD;
&#xD;
               -  Asymptomatic cases of SARS-CoV-2 infection with treatment performed more than 10&#xD;
                  days after first positive test for SARS-CoV-2&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>João Pedro Marto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stroke Center, Department of Neurology, Lausanne University Hospital, Lausanne, Switzerland and Deparment of Neurology, Hospital de Egas Moniz, Lisbon, Portugal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>George Ntaios, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Davide Strambo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stroke Centre, Neurology Service, Lausanne University Hospital, Lausanne, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patrik Michel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stroke Centre, Neurology Service, Lausanne University Hospital, Lausanne, Switzerland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>João Pedro Marto, MD</last_name>
    <phone>+351210432179</phone>
    <email>joao.pedro.seabra.marto@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lausanne University Hospital</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrik Michel, MD</last_name>
      <email>Patrik.Michel@chuv.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 16, 2021</study_first_submitted>
  <study_first_submitted_qc>May 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2021</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Universitaire Vaudois</investigator_affiliation>
    <investigator_full_name>Joao Pedro Marto</investigator_full_name>
    <investigator_title>João Pedro Marto</investigator_title>
  </responsible_party>
  <keyword>Intravenous thrombolysis</keyword>
  <keyword>Endovascular treatment</keyword>
  <keyword>Mechanical thrombectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

